Strengthening Research into the Bioactive Functions and Pharmacological Effects of Mushrooms
First written in FY2016. 35 of 39 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-08-12.
0 other companies' latest entry also says "Restated".
- 2026-08-12RestatedEarnings
「In development and research, the company has worked to improve product quality, develop new products and varieties with high added value, and pursue research into mushrooms' pharmacological effects and functional properties.」
The company continues research into the pharmacological effects and functionality of mushrooms. - FY2026AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the fiscal year was ¥734 million. Of the results obtained from R&D activities to date, the publicly disclosed results are as follows.」
The company recorded ¥734 million in R&D expenses and disclosed variety registrations in South Korea and Europe, germination research on ectomycorrhizal fungi, shiitake genetic research and related results. - 2026-06-05RestatedGeneral Meetings of Shareholders
「We will continue to focus on improving product quality, developing highly productive, quality-focused cultivation technologies, developing new varieties, and researching the pharmacological effects and functionality of mushrooms, while also working with other departments to develop new businesses.」
The company continues its research and development policy covering new varieties, cultivation technology, and research into the pharmacological effects and functionality of mushrooms. - FY2026-H1AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the interim consolidated period was ¥371 million. Of the results obtained from R&D activities to date, the publicly disclosed results are as follows.」
The company recorded ¥371 million in R&D expenses for the interim period and made academic presentations on shiitake genetic research, germination research on ectomycorrhizal fungi, and the results of joint research with Osaka Metropolitan University. - FY2025AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the fiscal year was ¥732 million.」
R&D expenses increased from ¥671 million in the previous fiscal year to ¥732 million. The company put its research into new varieties, cultivation technologies, shiitake enzymes and the functionality of Pleurotus mushrooms containing ergothioneine into practice through academic presentations, paper publications and variety registrations. - FY2025-H1AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the interim consolidated period was ¥361 million.」
The company recorded ¥361 million in R&D expenses and continued research on mushroom varieties, cultivation technologies and health functionality. It also reported an academic presentation resulting from joint research with Osaka Metropolitan University and publication of a paper on a randomized controlled trial of the skin functions of Pleurotus mushrooms rich in ergothioneine. - FY2024AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the fiscal year was ¥671 million.」
R&D expenses increased from ¥242 million to ¥671 million, and the company put the results of its research into functionality, varieties and cultivation technologies into practice through variety registrations, cultivation-container patents and clinical trials of mushroom consumption. - FY2024-Q3AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the cumulative third quarter was ¥506 million. Title: Effects of mushroom consumption on increased short-chain fatty acids in the gut and IgA production: a randomized, placebo-controlled, double-blind, parallel-group study」
The company recorded ¥506 million in R&D expenses and put its health functionality research into practice through academic presentations, including a randomized controlled trial on mushroom consumption and gut short-chain fatty acids and IgA production. - FY2024-Q2AdvancedAnnual report
「Title: Changes in and comparison of the activity of various glycoside hydrolases during fruiting-body formation in 2 shiitake (Lentinula edodes) varieties Presentation date: 7 August 2023 Conference: 26th Annual Meeting of the Japanese Society of Mushroom Science Joint research with Osaka Metropolitan University」
The company presented at an academic conference, as joint research with Osaka Metropolitan University, a study of enzyme activity during fruiting-body formation in shiitake mushrooms. R&D expenditure amounted to ¥353 million for the cumulative second quarter. - FY2024-Q1AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the cumulative first quarter was ¥176 million.」
The company recorded ¥176 million in R&D expenses and continued research on new varieties, improvements to existing varieties, cultivation technologies and the health functionality of mushrooms. - FY2023AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the fiscal year was ¥242 million. Of the results obtained from R&D activities to date, the publicly disclosed results are as follows.」
The company recorded ¥242 million in R&D expenses and disclosed the results of joint research on cultivation containers and harvesting methods, buna-shimeji variety registration, vitamin D2, and gut short-chain fatty acids and IgA. - FY2023-Q3AdvancedAnnual report
「The company conducted joint research with Metagen, Inc. (head office: Tsuruoka, Yamagata Prefecture; Representative Director, President, CEO and CGDO: Fukuda Shinji (福田 真嗣)). The research found in humans that consuming mushrooms continuously for 4 weeks increased short-chain fatty acids in the gut and showed a tendency toward increased IgA antibodies, leading to improved immune function. The results were accepted for publication in the scientific journal Frontiers in Nutrition.」
Joint research with Metagen on the effects in humans of consuming mushrooms for 4 weeks on gut short-chain fatty acids and IgA antibodies was accepted for publication in a scientific journal. R&D expenses amounted to ¥194 million, putting the results of the company's functional research into practice. - FY2023-Q2AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the cumulative second quarter was ¥121 million. Of the results obtained from R&D activities to date, the publicly disclosed results are as follows.」
The company recorded ¥121 million in R&D expenses and registered patents for cultivation containers and harvesting methods, conducted functional research on mushrooms with a high vitamin D2 content, and presented research on interspecific hybrids of Pleurotus species. - FY2023-Q1AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the cumulative first quarter was ¥66 million. Of the results obtained from R&D activities to date, the publicly disclosed results are as follows. Patent registrations (Domestic) Title of invention: Cultivation bottle cap for buna-shimeji mushrooms and method for cultivating buna-shimeji mushrooms Registration date: 2 June 2022 Registration number: 7083385」
The company recorded ¥66 million in R&D expenses and registered a domestic patent for a cultivation bottle cap and cultivation method for buna-shimeji mushrooms on 2 June 2022. In addition, it presented at an academic conference the results of joint research on mushrooms with a high vitamin D2 content and interspecific hybrids of Pleurotus species. - FY2022AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the fiscal year was ¥248 million, and the main results are as follows.」
The company recorded ¥248 million in R&D expenses and advanced patents for fatty-acid metabolism-promoting compounds and mushroom harvesting devices, variety registrations, and academic presentations and paper publications on functionality. - FY2022-Q3AdvancedAnnual report
「Title of invention: Mushroom harvesting device Registration date: 24 September 2021 Registration number: Patent No. 6948542」
The company reported a domestic patent registration for a mushroom harvesting device, a patent registration for a fatty-acid metabolism-promoting compound, a maitake plant patent, variety registrations and publication of functional research papers, putting its R&D results into practice. - FY2022-Q2AdvancedAnnual report
「The amount spent on research and development by the Group as a whole during the cumulative second quarter was ¥120 million, and the main results are as follows.」
The company recorded ¥120 million in R&D expenses and reported patent registrations for a fatty-acid metabolism-promoting compound and a mushroom harvesting device, a plant patent registration for maitake, and publication of papers on functionality. - FY2022-Q1AdvancedAnnual report
「Title of invention: Extraction method for a fatty-acid metabolism-promoting compound and fatty-acid metabolism-promoting agent Registration date: 28 May 2021 Registration number: 6890780」
In addition to registering a domestic patent relating to a fatty-acid metabolism-promoting compound, the company published joint research papers on the antipruritic effects of maitake and enzymes derived from Isaria cicadae, putting the results of its research into the health functionality of mushrooms into practice. - FY2021AdvancedAnnual report
「Title of invention: Lipid-soluble extract and extraction method for promoting the migration and proliferation of vascular endothelial cells, and angiogenesis-promoting agent and wound-healing agent Registration date: 24 March 2021 Registration number: 6857512」
The company registered a domestic patent relating to angiogenesis and wound healing using mushroom-derived compounds, putting the results of its bioactive function research into practice. - FY2021-Q3AdvancedAnnual report
「Title: Japanese mushroom consumption alters the lipid metabolomic profile of high-fat diet-fed mice Journal: Heliyon, 6(7), e04438 (2020) Joint research with the Faculty of Agriculture, Tohoku University」
The company published a joint research paper on the effects of mushroom consumption on the lipid metabolome of mice fed a high-fat diet, putting the results of its health functionality research into practice. - FY2021-Q2AdvancedAnnual report
「Title: Japanese mushroom consumption alters the lipid metabolomic profile of high-fat diet-fed mice Journal: Heliyon, 6(7), e04438 (2020) Joint research with the Faculty of Agriculture, Tohoku University」
The company published a joint research paper on the effects of mushroom consumption on the lipid metabolome of mice fed a high-fat diet, advancing research into health functionality. - FY2021-Q1AdvancedAnnual report
「Title Protective effects against UVB-induced skin damage from consuming marbled oyster mushrooms containing the antioxidant ergothioneine Presentation date: 17 May 2020 Conference: 74th Annual Meeting of the Japanese Society of Nutrition and Food Science Joint research with the Faculty of Pharmacy, Kanazawa University」
The company presented at an academic conference the results of joint research with the Faculty of Pharmacy, Kanazawa University, on the protective effects of consuming marbled oyster mushrooms against skin damage. - FY2020AdvancedAnnual report
「Patent registrations (Domestic) Title of invention: Cultivation method for porcini mushrooms Registration date: 14 June 2019 Registration number: Patent No. 6537927 (Overseas) Indonesia Title of invention: New variety of Pleurotus and method for producing it」
The company registered patents for a porcini cultivation method, a new Pleurotus variety and the functional properties of yamabushitake, and presented and published joint research on vitamin D2, the gut microbiota and related topics. - FY2020-Q3AdvancedAnnual report
「Title: Grifola frondosa extract and ergosterol reduce allergic reactions in an allergy mouse model by suppressing the degranulation of mast cells Journal: Bioscience, Biotechnology, and Biochemistry, 1-8, (2019)」
The company has advanced research into the functional and pharmacological effects of mushrooms, including publication of a paper on the suppression of allergic reactions by maitake extract and ergosterol. - FY2020-Q2AdvancedAnnual report
「Patent registrations (domestic): Title of invention: Cultivation method for porcini mushrooms; registration date: 14 June 2019. (Overseas) Indonesia: Title of invention: New variety of Pleurotus and method for producing it; registration date: 18 June 2019. United States: Title of invention: Patent for yamabushitake, “Agent for promoting the growth of nonpathogenic indigenous oral bacteria and improving the oral microbiota, and oral composition”; registration date: 20 August 2019.」
The company registered patents for a porcini cultivation method, a new Pleurotus variety and the functional properties of yamabushitake, putting its research results into practice. - FY2020-Q1AdvancedAnnual report
「Patent registrations (Domestic) Title of invention: Cultivation method for porcini mushrooms Registration date: 14 June 2019 Registration number: Patent No. 6537927 (Overseas) Indonesia Title of invention: New variety of Pleurotus and method for producing it Registration date: 18 June 2019 Registration number: IDP000059709 Academic presentation Title: “Protective effects of consuming maitake mushrooms with a high vitamin D2 content on UVB-induced skin damage” Presentation date: 7 June 2019 Conference: 71st Annual Meeting of the Japanese Society for Vitamins Joint research with the Faculty of Health and Nutrition, Osaka Shoin Women's University」
The company registered patents for a porcini cultivation method and a new Pleurotus variety, and presented joint research on the health benefits of maitake mushrooms with a high vitamin D2 content. - FY2019AdvancedAnnual report
「Patent registration (overseas): United States Title of invention: Shiitake HOKSY No. 8 strain (plant patent) / Title of invention: New species of Pleurotus sp. and method for producing it」
The company registered U.S. patents for a shiitake variety and a new Pleurotus species, and made multiple academic presentations and paper publications on functional research. - FY2019-Q3AdvancedAnnual report
「Patent registration (Overseas) United States Title of invention Shiitake HOKSY8 strain (plant patent) Registration date 9 October 2018 Registration number PP29740 Title of invention New species of Pleurotus sp. and method for producing the same Registration date 20 November 2018 Registration number US10,131,869」
In addition to registering U.S. patents for shiitake varieties and new Pleurotus species, the company has presented its functional and compositional research at academic conferences and published papers, putting its research results into practice. - FY2019-Q2AdvancedAnnual report
「Conference presentation Title Development of SSR markers for shiitake Presentation date 13 September 2018 Conference 22nd Annual Meeting of the Japanese Society of Mushroom Science Paper publication Title Effects of Dietary Intake of Japanese Mushrooms on Visceral Fat Accumulation and Gut Microbiota in Mice」
We advanced functional-property and variety research through a conference presentation on the development of SSR markers for shiitake and publications on mushroom consumption, visceral fat, gut microbiota, and maitake extract. - FY2019-Q1AdvancedAnnual report
「Title “Mechanism by which ergosterol inhibits degranulation in RBL-2H3 cells” Presentation date 13 May 2018 Conference 72nd Annual Meeting of the Japanese Society of Nutrition and Food Science Joint research with the Graduate School of Pharmaceutical Sciences, Tohoku University Title “Development of SSR markers for new varieties of Pleurotus” Presentation date 27 May 2018 Conference 62nd Annual Meeting of the Mycological Society of Japan」
We presented joint research findings at conferences on the mechanism of action of ergosterol and SSR markers for new Pleurotus varieties. We also published papers on the functional and health benefits of mushrooms. - FY2018AdvancedAnnual report
「Title “Consumption of edible mushrooms in Japan suppresses obesity in mice.” Presentation date 17 March 2018 Conference 2018 Annual Meeting of the Japan Society for Bioscience, Biotechnology, and Agrochemistry Joint research with the Graduate School of Agricultural Science, Tohoku University」
We presented joint research findings on edible mushroom consumption and obesity suppression at a conference, advancing functional-property research. - FY2018-Q3AdvancedAnnual report
「Title “Research on trehalase in the autolysis of oyster mushroom fruiting bodies” Presentation date 7 September 2017 Conference 21st Annual Meeting of the Japanese Society of Mushroom Science Joint research with Osaka Prefecture University Title “Palatability of venison hamburgers containing various mushroom pastes” Presentation date 26 September 2017 Conference 51st Annual Meeting of the Japanese Society for Taste and Smell Joint research with Nagano Women’s Junior College Title “Analysis of the lipid metabolism-promoting effects of buna-shimeji using HepG2 cells” Presentation date 9 December 2017 Conference 15th Annual Meeting of the Japanese Society for Functional Food and Medical Sciences」
We added conference presentations based on joint research on oyster mushroom autolysis, the palatability of mushroom paste, and the lipid metabolism-promoting effects of buna-shimeji, further advancing functional-property research. - FY2018-Q2AdvancedAnnual report
「Title “Chitinase and other hydrolytic enzymes in mushroom autolysis” Presentation date 23 August 2017 Conference 31st Annual Meeting of the Japanese Society for Chitin and Chitosan Joint research with Osaka Prefecture University」
We added research findings on mushroom components and functional properties, including a conference presentation based on joint research with Osaka Prefecture University. - FY2018-Q1AdvancedAnnual report
「Patent application Title of invention Method for Extracting a Fatty Acid Metabolism-Promoting Compound and Fatty Acid Metabolism-Promoting Agent Application number 2017-78469 Application date 11 April 2017 Patent registration (Hong Kong) Title of invention New species of Pleurotus sp. and method for producing the same Registration number HK1208778 Registration date 21 April 2017 Conference presentation Title “PPARδ activation capacity and skeletal muscle function-improving effects of maitake extract” Presentation date 20 May 2017 Conference 71st Annual Meeting of the Japanese Society of Nutrition and Food Science Joint research with the Graduate School of Agricultural and Life Sciences, The University of Tokyo」
We filed a patent application concerning a fatty acid metabolism-promoting compound, registered a Hong Kong patent for a new species of Pleurotus sp., and presented research findings on the functional properties of maitake extract at a conference. - FY2017AdvancedAnnual report
「Title “Angiogenesis-promoting effects of maitake (Grifola frondosa) on human umbilical vein endothelial cells” Presentation date 18 March 2017 Conference 2017 Annual Meeting of the Japan Society for Bioscience, Biotechnology, and Agrochemistry Joint research with the Graduate School of Agricultural Science, Tohoku University」
In addition to conference presentations based on joint research into the functional properties of mushroom-derived compounds, we registered and filed patents and published papers, putting our research activities into concrete form. - FY2017-Q3AdvancedAnnual report
「Title “Anti-inflammatory effects of king oyster mushroom extract on LPS-stimulated HT-29 intestinal cells” Presentation date 19 November 2016 Conference 71st Annual Meeting of the Japanese Society of Nutrition and Food Science, Chubu Branch」
We advanced research into the functional properties of mushrooms, including presenting research findings on the anti-inflammatory effects of king oyster mushroom extract at a conference. - FY2017-Q2AdvancedAnnual report
「Oral conference presentations Title Search for mushroom-derived tyrosinase inhibitors Presentation date 23 July 2016 Conference West Japan Branch Meeting of the Mycological Society of Japan Joint research with Osaka Prefecture University Title Search for mushroom-derived tyrosinase inhibitors Presentation date 8 September 2016 Conference 20th Annual Meeting of the Japanese Society of Mushroom Science」
We conducted conference presentations and joint research with Osaka Prefecture University on the search for mushroom-derived tyrosinase inhibitors. - FY2017-Q1RestatedAnnual report
「We worked to strengthen our quality-control systems, develop high-value-added new products, and investigate the pharmacological effects and functional properties of mushrooms.」
Quality, new products, and the pharmacological effects and functional properties of mushrooms continue to be major research themes. - FY2016First statedAnnual report
「At the Mushroom Research Institute, we will continue to accelerate our efforts to develop and improve new varieties and research the physiological functions of mushrooms.」
Research into the health benefits of mushrooms is being advanced as a research theme alongside variety development and improvement.